Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""MULTIPLE myeloma"" wg kryterium: Temat


Starter badań:

Tytuł :
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.
Autorzy :
Costa LJ; Division of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA. .
Derman BA; Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL, USA.
Bal S; Division of Hematology and Oncology, Department of Medicine, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Sidana S; Department of Medicine, Stanford University, Stanford, CA, USA.
Chhabra S; Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Silbermann R; Division of Hematology and Medical Oncology, Oregon Health & Science University, Knight Cancer Institute, Portland, OR, USA.
Ye JC; Division of Hematology and Oncology, Department of Internal Medicine, Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA.
Cook G; Haematology & Myeloma Studies, Section of Experimental Haematology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
Cornell RF; Division of Hematology & Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Holstein SA; Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Shi Q; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Omel J; Independent Patient Advocate, Omaha, NE, USA.
Callander NS; Carbone Cancer Center, University of Wisconsin, Madison, WI, USA.
Chng WJ; National University Health System, Singapore, Singapore.
Hungria V; Clinica São Germano, São Paulo, Brazil.
Maiolino A; Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Stadtmauer E; University of Pennsylvania, Philadelphia, PA, USA.
Giralt S; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Pasquini M; Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Jakubowiak AJ; Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL, USA.
Morgan GJ; New York University Langone Health, New York, NY, USA.
Krishnan A; City of Hope, Duarte, CA, USA.
Jackson GH; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
Mohty M; Hôpital Saint-Antoine, Paris, France.
Mateos MV; Department of Haematology, University Hospital of Salamanca, Salamanca, Spain.
Dimopoulos MA; School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Facon T; Service des Maladies du Sang, Centre Hospitalier Universitaire (CHU) Lille, University of Lille, Lille, France.
Spencer A; Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VA, Australia.
Miguel JS; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada Instituto de Investigacion Sanitaria de Navarra, Pamplona, Spain.
Hari P; Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
Usmani SZ; Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Charlotte, NC, USA.
Manier S; Department of Hematology, Université de Lille, CHU, Lille, France.
McCarthy P; Roswell Park Cancer Institute, Buffalo, NY, USA.
Kumar S; Department of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
Gay F; Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy.
Paiva B; Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada Instituto de Investigacion Sanitaria de Navarra, Pamplona, Spain.
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Jan; Vol. 35 (1), pp. 18-30. Date of Electronic Publication: 2020 Aug 11.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Multiple Myeloma/*epidemiology
Multiple Myeloma/*pathology
Neoplasm, Residual/*diagnosis
Neoplasm, Residual/*epidemiology
Clinical Trials as Topic ; Diagnostic Imaging ; Disease Management ; Drug Collateral Sensitivity ; Global Health ; Humans ; Molecular Diagnostic Techniques/methods ; Molecular Diagnostic Techniques/standards ; Multiple Myeloma/therapy ; Neoplastic Cells, Circulating/metabolism ; Neoplastic Cells, Circulating/pathology ; Outcome Assessment, Health Care ; Population Surveillance ; Reproducibility of Results ; Smoldering Multiple Myeloma/epidemiology ; Smoldering Multiple Myeloma/pathology ; Time Factors
Czasopismo naukowe
Tytuł :
MicroRNAs in urine as diagnostic biomarkers for multiple myeloma.
Autorzy :
Li J; Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.; Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China.
Wang C; Medical Laboratory Center, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Meng Q; Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.; Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China.
Hu Z; Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.; Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China.
Hu M; Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.; Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China.
Zhang M; Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.; Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China.; Clinical Laboratory Medicine, Peking University Ninth School of Clinical Medicine, Beijing, China.
Pokaż więcej
Źródło :
International journal of laboratory hematology [Int J Lab Hematol] 2021 Apr; Vol. 43 (2), pp. 227-234. Date of Electronic Publication: 2020 Oct 17.
Typ publikacji :
Journal Article
MeSH Terms :
Biomarkers, Tumor*
Cell-Free Nucleic Acids*
MicroRNAs*/urine
Multiple Myeloma/*diagnosis
Multiple Myeloma/*genetics
Adult ; Aged ; Aged, 80 and over ; Computational Biology/methods ; Female ; Gene Expression Profiling/methods ; Gene Expression Regulation ; Humans ; Kaplan-Meier Estimate ; Liquid Biopsy/methods ; Male ; Middle Aged ; Multiple Myeloma/mortality ; Multiple Myeloma/urine ; Prognosis ; RNA Interference ; ROC Curve ; Real-Time Polymerase Chain Reaction ; Transcriptome ; Urinalysis/methods
Czasopismo naukowe
Tytuł :
Co-evolution of tumor and immune cells during progression of multiple myeloma.
Autorzy :
Liu R; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.
Gao Q; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.
Foltz SM; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.
Fowles JS; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Yao L; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.
Wang JT; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.
Cao S; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.
Sun H; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.
Wendl MC; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.; Department of Genetics, Washington University in St. Louis, St. Louis, MO, USA.; Department of Mathematics, Washington University in St. Louis, St. Louis, MO, USA.
Sethuraman S; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.
Weerasinghe A; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.
Rettig MP; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Storrs EP; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.
Yoon CJ; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.
Wyczalkowski MA; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.
McMichael JF; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.
Kohnen DR; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
King J; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Goldsmith SR; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
O'Neal J; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Fulton RS; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.
Fronick CC; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.
Ley TJ; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Jayasinghe RG; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.
Fiala MA; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Oh ST; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.; Center for Human Immunology and Immunotherapy Programs, Washington University in St. Louis, St. Louis, MO, USA.
DiPersio JF; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.; Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO, USA.
Vij R; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA. .; Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO, USA. .
Ding L; Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA. .; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA. .; Department of Genetics, Washington University in St. Louis, St. Louis, MO, USA. .; Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO, USA. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2021 May 07; Vol. 12 (1), pp. 2559. Date of Electronic Publication: 2021 May 07.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
B-Lymphocytes/*metabolism
Gene Expression Regulation, Neoplastic/*genetics
Multiple Myeloma/*genetics
Multiple Myeloma/*immunology
Neoplasm Recurrence, Local/*genetics
Tumor Microenvironment/*immunology
Aged ; B-Lymphocytes/cytology ; B-Lymphocytes/immunology ; Cell Lineage ; Clonal Evolution/genetics ; Cohort Studies ; Disease Progression ; Female ; Gene Expression Regulation, Neoplastic/immunology ; Haplotypes ; Humans ; Interleukin-1beta/blood ; Interleukin-6/blood ; Male ; Mass Spectrometry ; Middle Aged ; Multigene Family ; Multiple Myeloma/blood ; Multiple Myeloma/pathology ; Mutation ; Neoplasm Recurrence, Local/blood ; Neoplasm Recurrence, Local/immunology ; Proto-Oncogene Proteins c-fos/blood ; Proto-Oncogene Proteins c-jun/blood ; RNA-Seq ; Signal Transduction/genetics ; Signal Transduction/immunology ; Single-Cell Analysis
Czasopismo naukowe
Tytuł :
[Multiple myeloma-soon curable?]
Autorzy :
Goldschmidt H; Medizinische Klinik V und Nationales Centrum für Tumorerkrankungen (NCT), Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland. .
Pokaż więcej
Transliterated Title :
Multiples Myelom – bald heilbar?
Źródło :
Der Internist [Internist (Berl)] 2021 May; Vol. 62 (5), pp. 562-570. Date of Electronic Publication: 2021 Mar 30.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Multiple Myeloma*/diagnosis
Multiple Myeloma*/therapy
Antibodies, Monoclonal ; Germany ; Humans ; Proteasome Inhibitors ; T-Lymphocytes
Czasopismo naukowe
Tytuł :
The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma.
Autorzy :
Jin Y; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing, 100730, China.; Department of Hematology, People's Hospital of Jiangsu Province, Nanjing, China.
Yu X; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing, 100730, China.
Du J; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing, 100730, China.
Li H; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing, 100730, China.
Tang W; Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.
Jia C; Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Zan Y; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing, 100730, China.
Chen M; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing, 100730, China.
Zhang Y; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing, 100730, China.
Yu M; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing, 100730, China.
Rong W; Department of Hepatobiliary Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Zhou D; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing, 100730, China.
Zhuang J; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing, 100730, China. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 May; Vol. 100 (5), pp. 1251-1260. Date of Electronic Publication: 2021 Mar 08.
Typ publikacji :
Journal Article
MeSH Terms :
Multiple Myeloma/*genetics
Proto-Oncogene Proteins c-myc/*genetics
Adult ; Aged ; Aged, 80 and over ; Cell Line, Tumor ; Chromosome Aberrations ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Middle Aged ; Multiple Myeloma/diagnosis ; Multiple Myeloma/pathology ; Prognosis ; RNA, Messenger/genetics
Czasopismo naukowe
Tytuł :
Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy.
Autorzy :
Eveillard M; Clinical Chemistry Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Korde N; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ciardiello A; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Diamond B; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lesokhin A; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mailankody S; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Smith E; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hassoun H; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hultcrantz M; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Shah U; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lu S; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Salcedo M; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Werner K; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rispoli J; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mastey D; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Landgren O; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Thoren K; Clinical Chemistry Service, Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: .
Pokaż więcej
Źródło :
Clinica chimica acta; international journal of clinical chemistry [Clin Chim Acta] 2021 May; Vol. 516, pp. 136-141. Date of Electronic Publication: 2021 Feb 02.
Typ publikacji :
Journal Article
MeSH Terms :
Multiple Myeloma*/diagnosis
Multiple Myeloma*/drug therapy
Animals ; Antibodies, Monoclonal ; Follow-Up Studies ; Humans ; Sheep ; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Czasopismo naukowe
Tytuł :
Chronic Diarrhea as the Presenting Feature of Amyloidosis with Multiple Myeloma: A Case Report Diagnosed by a Myocardial Biopsy.
Autorzy :
Otagiri S; Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Japan.
Nakajima S; Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Japan.
Katsurada T; Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Japan.
Sakurai K; Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Japan.
Yamanashi K; Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Japan.
Ara T; Department of Hematology, Hokkaido University Hospital, Japan.
Takakuwa E; Department of Surgical Pathology, Hokkaido University Hospital, Japan.
Mitsuhashi T; Department of Surgical Pathology, Hokkaido University Hospital, Japan.
Sakamoto N; Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Japan.
Pokaż więcej
Źródło :
Internal medicine (Tokyo, Japan) [Intern Med] 2021 Apr 15; Vol. 60 (8), pp. 1197-1203. Date of Electronic Publication: 2020 Nov 16.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Amyloidosis*/complications
Amyloidosis*/diagnosis
Multiple Myeloma*/complications
Multiple Myeloma*/diagnosis
Aged ; Biopsy ; Diarrhea/etiology ; Echocardiography ; Female ; Humans
Czasopismo naukowe
Tytuł :
Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton's Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease.
Autorzy :
Ziouti F; Department of Internal Medicine II, University Hospital Würzburg, 97080 Würzburg, Germany.
Rummler M; Research Centre, Shriners Hospital for Children-Canada, Montreal, QC H4A 0A9, Canada.; Department of Pediatric Surgery, McGill University, Montreal, QC H4A 3J1, Canada;.; Julius Wolff Institute and Berlin Institute of Health Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.
Steyn B; Research Centre, Shriners Hospital for Children-Canada, Montreal, QC H4A 0A9, Canada.; Department of Pediatric Surgery, McGill University, Montreal, QC H4A 3J1, Canada;.
Thiele T; Julius Wolff Institute and Berlin Institute of Health Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.
Seliger A; Julius Wolff Institute and Berlin Institute of Health Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.
Duda GN; Julius Wolff Institute and Berlin Institute of Health Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.
Bogen B; Institute of Clinical Medicine, University of Oslo and Department of Immunology, Oslo University Hospital, 0424 Oslo, Norway.
Willie BM; Research Centre, Shriners Hospital for Children-Canada, Montreal, QC H4A 0A9, Canada.; Department of Pediatric Surgery, McGill University, Montreal, QC H4A 3J1, Canada;.; Julius Wolff Institute and Berlin Institute of Health Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.
Jundt F; Department of Internal Medicine II, University Hospital Würzburg, 97080 Würzburg, Germany.; Comprehensive Cancer Center Mainfranken, 97080 Würzburg, Germany.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2021 Apr 07; Vol. 22 (8). Date of Electronic Publication: 2021 Apr 07.
Typ publikacji :
Journal Article
MeSH Terms :
Stress, Mechanical*
Acrylamides/*administration & dosage
Bone Diseases/*etiology
Bone Diseases/*prevention & control
Multiple Myeloma/*complications
Protein Kinase Inhibitors/*administration & dosage
Pyrimidines/*administration & dosage
Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors ; Animals ; Bone Diseases/pathology ; Disease Models, Animal ; Humans ; Mice ; Multiple Myeloma/drug therapy ; Multiple Myeloma/metabolism ; Osteolysis/etiology ; Osteolysis/pathology ; Osteolysis/prevention & control ; X-Ray Microtomography
Czasopismo naukowe
Tytuł :
[Multiple myeloma in an elderly patient with history of breast cancer : the value of multidisciplinary oncogeriatric collaboration].
Autorzy :
Legros M; Service des Urgences, CHR Citadelle, Liège, Belgique.
Bouillon AS; Service d'Hématologie, CHR Citadelle, Liège, Belgique.
Janin N; Service d'Oncologie, CHR Citadelle, Liège, Belgique.
Moonen M; Service de Néphrologie, CHR Citadelle, Liège, Belgique.
Louviaux I; Service d'Oncologie, CHR Citadelle, Liège, Belgique.
Salmon JP; Service d'Oncologie, CHR Citadelle, Liège, Belgique.
Berg N; Service de Gériatrie, CHR Citadelle, Liège, Belgique.
Servais P; Service de Gériatrie, CHR Citadelle, Liège, Belgique.
Pokaż więcej
Transliterated Title :
Cas clinique. Prise en charge d’un myélome multiple chez une patiente âgée aux antécédents de néoplasie mammaire : intérêt d’une collaboration multidisciplinaire onco-gériatrique.
Źródło :
Revue medicale de Liege [Rev Med Liege] 2021 Apr; Vol. 76 (4), pp. 232-238.
Typ publikacji :
Case Reports
MeSH Terms :
Breast Neoplasms*/complications
Breast Neoplasms*/therapy
Frailty*
Multiple Myeloma*/complications
Multiple Myeloma*/diagnosis
Multiple Myeloma*/therapy
Aged ; Geriatric Assessment ; Humans ; Quality of Life
Raport
Tytuł :
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study.
Autorzy :
Iida S; Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan. .
Ishikawa T; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Min CK; Seoul St. Mary's Hospital, Seoul, South Korea.
Kim K; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Yeh SP; China Medical University Hospital, Taichung, Taiwan.
Usmani SZ; Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.
Mateos MV; University Hospital of Salamanca/IBSAL, Salamanca, Spain.
Nahi H; Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden.
Heuck C; Janssen Research & Development, LLC, Spring House, PA, USA.
Qin X; Janssen Research & Development, LLC, Raritan, NJ, USA.
Parasrampuria DA; Janssen Research & Development, LLC, Spring House, PA, USA.
Gries KS; Janssen Research & Development, LLC, Spring House, PA, USA.
Qi M; Janssen Research & Development, LLC, Spring House, PA, USA.
Bahlis N; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada.
Ito S; Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Iwate, Japan.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Apr; Vol. 100 (4), pp. 1065-1077. Date of Electronic Publication: 2021 Feb 18.
Typ publikacji :
Clinical Trial, Phase III; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms :
Salvage Therapy*
Antibodies, Monoclonal/*therapeutic use
Antineoplastic Agents, Immunological/*therapeutic use
Asian Continental Ancestry Group/*statistics & numerical data
Multiple Myeloma/*drug therapy
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/pharmacokinetics ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/pharmacokinetics ; Asian Continental Ancestry Group/psychology ; Body Weight ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Injections, Subcutaneous ; Japan/epidemiology ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Multiple Myeloma/ethnology ; Multiple Myeloma/mortality ; Multiple Myeloma/therapy ; Neutropenia/chemically induced ; Patient Satisfaction ; Progression-Free Survival ; Republic of Korea/epidemiology ; Taiwan/epidemiology ; Young Adult
Czasopismo naukowe
Tytuł :
Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma.
Autorzy :
Kazandjian D; Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.; Myeloma Program, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.
Dew A; Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.; Hematology-Oncology Department, John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Hill E; Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Ramirez EG; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Morrison C; Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Mena E; Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Lindenberg L; Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Yuan C; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Maric I; Hematology Service, Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland, USA.
Wang HW; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Calvo K; Hematology Service, Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland, USA.
Dulau-Florea A; Hematology Service, Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland, USA.
Roswarski J; Multiple Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.; Hematology-Oncology Department, John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Emanuel M; Office Research Nursing, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Braylan R; Hematology Service, Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland, USA.
Turkbey B; Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Choyke P; Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Camphausen K; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Stetler-Stevenson M; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Steinberg SM; Biostatistics & Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Figg WD; Molecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
C Jones J; Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.; Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Apr; Vol. 26 (4), pp. 288-e541. Date of Electronic Publication: 2021 Mar 10.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Multiple Myeloma*/drug therapy
Multiple Myeloma*/radiotherapy
Antibodies, Monoclonal, Humanized/*therapeutic use
Immune Checkpoint Inhibitors/*therapeutic use
Aged ; Aged, 80 and over ; COVID-19 ; Female ; Humans ; Male ; Middle Aged ; Pandemics ; Pilot Projects
Czasopismo naukowe
Tytuł :
Management of acute spinal cord compression in multiple myeloma.
Autorzy :
Chen B; Department of Hematology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, China.
Cai L; Department of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071, China.
Zhou F; Department of Hematology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, China. Electronic address: .
Pokaż więcej
Źródło :
Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2021 Apr; Vol. 160, pp. 103205. Date of Electronic Publication: 2020 Dec 30.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Multiple Myeloma*/complications
Multiple Myeloma*/therapy
Spinal Cord Compression*/diagnosis
Spinal Cord Compression*/etiology
Spinal Cord Compression*/therapy
Humans
Czasopismo naukowe
Tytuł :
Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Autorzy :
Vozella F; Multiple Myeloma GIMEMA Lazio Group, Via Casilina 5, 00182, Rome, Italy. .
Siniscalchi A; Multiple Myeloma GIMEMA Lazio Group, Via Casilina 5, 00182, Rome, Italy.
Rizzo M; Multiple Myeloma GIMEMA Lazio Group, Via Casilina 5, 00182, Rome, Italy.
Za T; Multiple Myeloma GIMEMA Lazio Group, Via Casilina 5, 00182, Rome, Italy.
Antolino G; Multiple Myeloma GIMEMA Lazio Group, Via Casilina 5, 00182, Rome, Italy.
Coppetelli U; Multiple Myeloma GIMEMA Lazio Group, Via Casilina 5, 00182, Rome, Italy.
Piciocchi A; Multiple Myeloma GIMEMA Lazio Group, Via Casilina 5, 00182, Rome, Italy.
Andriani A; Multiple Myeloma GIMEMA Lazio Group, Via Casilina 5, 00182, Rome, Italy.
Annibali O; Multiple Myeloma GIMEMA Lazio Group, Via Casilina 5, 00182, Rome, Italy.
De Rosa L; Multiple Myeloma GIMEMA Lazio Group, Via Casilina 5, 00182, Rome, Italy.
Cimino G; Multiple Myeloma GIMEMA Lazio Group, Via Casilina 5, 00182, Rome, Italy.
La Verde G; Multiple Myeloma GIMEMA Lazio Group, Via Casilina 5, 00182, Rome, Italy.
De Stefano V; Multiple Myeloma GIMEMA Lazio Group, Via Casilina 5, 00182, Rome, Italy.
Cantonetti M; Multiple Myeloma GIMEMA Lazio Group, Via Casilina 5, 00182, Rome, Italy.
di Toritto TC; Multiple Myeloma GIMEMA Lazio Group, Via Casilina 5, 00182, Rome, Italy.
Petrucci MT; Multiple Myeloma GIMEMA Lazio Group, Via Casilina 5, 00182, Rome, Italy.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Apr; Vol. 100 (4), pp. 1059-1063. Date of Electronic Publication: 2021 Feb 02.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Antineoplastic Agents, Immunological/*therapeutic use
Multiple Myeloma/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/adverse effects ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bortezomib/administration & dosage ; Clinical Trials, Phase II as Topic/statistics & numerical data ; Disease-Free Survival ; Drug Resistance, Neoplasm ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Kaplan-Meier Estimate ; Lenalidomide/administration & dosage ; Male ; Middle Aged ; Multicenter Studies as Topic/statistics & numerical data ; Multiple Myeloma/mortality ; Multiple Myeloma/therapy ; Myeloma Proteins/analysis ; Oligopeptides/administration & dosage ; Progression-Free Survival ; Thalidomide/administration & dosage ; Thalidomide/analogs & derivatives
Czasopismo naukowe
Tytuł :
Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients.
Autorzy :
Geng C; Department of Hematology, Beijing Chaoyang Hospital, Capital medical University, Beijing, China.
Yang G; Department of Hematology, Beijing Chaoyang Hospital, Capital medical University, Beijing, China.
Wang H; Department of Hematology, Beijing Chaoyang Hospital, Capital medical University, Beijing, China.
Wu Y; Department of Hematology, Beijing Chaoyang Hospital, Capital medical University, Beijing, China.
Leng Y; Department of Hematology, Beijing Chaoyang Hospital, Capital medical University, Beijing, China.
Zhou H; Department of Hematology, Beijing Chaoyang Hospital, Capital medical University, Beijing, China.
Zhang Z; Department of Hematology, Beijing Chaoyang Hospital, Capital medical University, Beijing, China.
Jian Y; Department of Hematology, Beijing Chaoyang Hospital, Capital medical University, Beijing, China.
Chen W; Department of Hematology, Beijing Chaoyang Hospital, Capital medical University, Beijing, China.
Pokaż więcej
Źródło :
Leukemia & lymphoma [Leuk Lymphoma] 2021 Apr; Vol. 62 (4), pp. 883-890. Date of Electronic Publication: 2020 Dec 04.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Multiple Myeloma*/diagnosis
Multiple Myeloma*/therapy
Humans ; Immunoglobulins ; Prognosis ; Progression-Free Survival ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Iguratimod-encapsulating PLGA-NPs induce human multiple myeloma cell death via reactive oxygen species and Caspase-dependent signalling.
Autorzy :
Wang F; Department of Biochemistry and Molecular Biology, Medical School of Southeast University, # 87 Dingjiaqiao Road, Nanjing 210009, China.
Younis M; Department of Biochemistry and Molecular Biology, Medical School of Southeast University, # 87 Dingjiaqiao Road, Nanjing 210009, China; Key Laboratory for Developmental Genes and Human Disease, Ministry of Education, Institute of Life Sciences, Southeast University, Nanjing 210096, China.
Luo Y; Department of Biochemistry and Molecular Biology, Medical School of Southeast University, # 87 Dingjiaqiao Road, Nanjing 210009, China.
Zhang L; Department of Biochemistry and Molecular Biology, Medical School of Southeast University, # 87 Dingjiaqiao Road, Nanjing 210009, China.
Yuan L; Department of Biochemistry and Molecular Biology, Medical School of Southeast University, # 87 Dingjiaqiao Road, Nanjing 210009, China; Key Laboratory for Developmental Genes and Human Disease, Ministry of Education, Institute of Life Sciences, Southeast University, Nanjing 210096, China. Electronic address: .
Pokaż więcej
Źródło :
International immunopharmacology [Int Immunopharmacol] 2021 Jun; Vol. 95, pp. 107532. Date of Electronic Publication: 2021 Mar 20.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*administration & dosage
Chromones/*administration & dosage
Multiple Myeloma/*drug therapy
Nanoparticles/*administration & dosage
Polylactic Acid-Polyglycolic Acid Copolymer/*administration & dosage
Sulfonamides/*administration & dosage
Animals ; Apoptosis/drug effects ; Caspase 3/metabolism ; Caspase 9/metabolism ; Cell Cycle Checkpoints/drug effects ; Cell Line, Tumor ; Cell Movement/drug effects ; Cell Proliferation/drug effects ; Humans ; Male ; Mice, Inbred BALB C ; Mice, Nude ; Multiple Myeloma/metabolism ; Reactive Oxygen Species/metabolism ; Signal Transduction/drug effects
Czasopismo naukowe
Tytuł :
Upregulation of ATIC in multiple myeloma tissues based on tissue microarray and gene microarrays.
Autorzy :
Li R; Medical School of Chinese PLA, Beijing, China.; Department of Scientific Research, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Chen G; Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Dang Y; Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
He R; Departments of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Liu A; Departments of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Ma J; Departments of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Wang C; Department of Clinical Laboratory, Chinese PLA General Hospital, Beijing, China.
Pokaż więcej
Źródło :
International journal of laboratory hematology [Int J Lab Hematol] 2021 Jun; Vol. 43 (3), pp. 409-417. Date of Electronic Publication: 2020 Nov 23.
Typ publikacji :
Journal Article
MeSH Terms :
Up-Regulation*
Hydroxymethyl and Formyl Transferases/*genetics
Multienzyme Complexes/*genetics
Multiple Myeloma/*genetics
Nucleotide Deaminases/*genetics
Gene Expression Regulation, Neoplastic ; Humans ; Multiple Myeloma/diagnosis ; Oligonucleotide Array Sequence Analysis ; Prognosis ; RNA, Messenger/genetics
Czasopismo naukowe
Tytuł :
The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database.
Autorzy :
Cherniawsky HM; University of Alberta, Edmonton, Alberta.
Kukreti V; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON.
Reece D; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON.
Masih-Khan E; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada; Canadian Myeloma Research Group, Toronto, Ontario. .
McCurdy A; The Ottawa Hospital, Ottawa, Ontario.
Jimenez-Zepeda VH; Tom Baker Cancer Centre, Calgary, Alberta.
Sebag M; Department of Oncology, Division of Hematology, McGill University, Montreal, QC.
Song K; BC Cancer, Vancouver General Hospital, British Columbia.
White D; Queen Elizabeth II Health Sciences Centre. Dalhousie University, Halifax, Nova Scotia.
Stakiw J; Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, Saskatchewan.
LeBlanc R; Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, Quebec.
Reiman A; Department of Oncology, Saint John Regional Hospital, Saint John, NB.
Aslam M; Allan Blair Cancer Centre, Regina, Saskatchewan.
Louzada M; London Regional Cancer Center, London, Ontario.
Kotb R; Cancer Care Manitoba, Winnipeg, Manitoba.
Gul E; Canadian Myeloma Research Group, Toronto, Ontario.
Atenafu E; Canadian Myeloma Research Group, Toronto, Ontario.
Venner CP; Cross Cancer Institute, University of Alberta, Edmonton, Alberta.
Pokaż więcej
Źródło :
Haematologica [Haematologica] 2021 Jun 01; Vol. 106 (6), pp. 1733-1736. Date of Electronic Publication: 2021 Jun 01.
Typ publikacji :
Letter
MeSH Terms :
Multiple Myeloma*/drug therapy
Multiple Myeloma*/epidemiology
Antineoplastic Combined Chemotherapy Protocols ; Bortezomib/therapeutic use ; Canada ; Dexamethasone/therapeutic use ; Disease-Free Survival ; Humans ; Lenalidomide/therapeutic use ; Maintenance Chemotherapy
Opinia redakcyjna
Tytuł :
Adhesion molecule immunophenotype of bone marrow multiple myeloma plasma cells impacts the presence of malignant circulating plasma cells in peripheral blood.
Autorzy :
Klimienė I; Hematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Radzevičius M; Institute of Biomedical Science, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Matuzevičienė R; Institute of Biomedical Science, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Sinkevič-Belliot K; Institute of Biomedical Science, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Kučinskienė ZA; Institute of Biomedical Science, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Pečeliūnas V; Hematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Pokaż więcej
Źródło :
International journal of laboratory hematology [Int J Lab Hematol] 2021 Jun; Vol. 43 (3), pp. 403-408. Date of Electronic Publication: 2020 Nov 13.
Typ publikacji :
Journal Article
MeSH Terms :
Bone Marrow/*pathology
Cell Adhesion Molecules/*analysis
Multiple Myeloma/*pathology
Neoplastic Cells, Circulating/*pathology
Plasma Cells/*pathology
Adult ; Aged ; Aged, 80 and over ; Antigens, CD/analysis ; Female ; Humans ; Immunophenotyping ; Male ; Middle Aged ; Multiple Myeloma/blood ; Multiple Myeloma/diagnosis ; Young Adult
Czasopismo naukowe
Tytuł :
Case of Kikuchi-Fujimoto disease associated with multiple myeloma.
Autorzy :
Fauzi LS; Internal Medicine, Pilgrim Hospital, Boston, Lincolnshire, UK .
Unadkat V; Internal Medicine, Pilgrim Hospital, Boston, Lincolnshire, UK.
Abd Hadi SNB; Department of Haematology, Pilgrim Hospital, Boston, Lincolnshire, UK.
Rinaldi C; Department of Haematology, Pilgrim Hospital, Boston, Lincolnshire, UK.
Pokaż więcej
Źródło :
BMJ case reports [BMJ Case Rep] 2021 May 20; Vol. 14 (5). Date of Electronic Publication: 2021 May 20.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Histiocytic Necrotizing Lymphadenitis*/complications
Histiocytic Necrotizing Lymphadenitis*/diagnosis
Histiocytic Necrotizing Lymphadenitis*/drug therapy
Lymphadenopathy*
Monoclonal Gammopathy of Undetermined Significance*
Multiple Myeloma*/complications
Multiple Myeloma*/diagnosis
Multiple Myeloma*/drug therapy
Biopsy ; Female ; Humans ; Middle Aged
Czasopismo naukowe
Tytuł :
tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma.
Autorzy :
Xu C; Department of Hematology, The Third Xiangya Hospital of Central South University, Changsha, 410000, China.
Liang T; Department of Blood Transfusion, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, 518000, China.
Zhang F; Department of Hematology, The Third Xiangya Hospital of Central South University, Changsha, 410000, China.
Liu J; Department of Hematology, The Third Xiangya Hospital of Central South University, Changsha, 410000, China. .
Fu Y; Department of Blood Transfusion, The Third Xiangya Hospital of Central South University, Changsha, 410000, China. .
Pokaż więcej
Źródło :
BMC bioinformatics [BMC Bioinformatics] 2021 May 11; Vol. 22 (1), pp. 238. Date of Electronic Publication: 2021 May 11.
Typ publikacji :
Journal Article
MeSH Terms :
Multiple Myeloma*/genetics
Biomarkers ; Computational Biology ; Humans ; RNA, Transfer/genetics
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies